- DAL-302 (dal-GenE-2) Trial: Evaluation of the effects of dalcetrapib on cardiovascular risk in a genetically defined population with a recent acute coronary syndrome. Sumanth Prabhu, MD. DalCore Pharmaceuticals.
CURRENTLY ENROLLING
view on clinicaltrials.gov